

PCT

WORLD INTELLECTUAL PROPERTY ORGANIZATION  
International Bureau



DX

601

INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification <sup>6</sup> : <b>C12N 15/19, C07K 14/52, G01N 33/53, 33/68, C12Q 1/68, C07K 16/24</b>		<b>A1</b>	(11) International Publication Number: <b>WO 99/32631</b>
			(43) International Publication Date: 1 July 1999 (01.07.99)
(21) International Application Number: <b>PCT/US98/26236</b>			(81) Designated States: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, UZ, VN, YU, ZW, ARIPO patent (GH, GM, KE, LS, MW, SD, SZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG).
(22) International Filing Date: 23 December 1998 (23.12.98)			
(30) Priority Data: 08/997,051 23 December 1997 (23.12.97) US			
(71) Applicant: HYSEQ, INC. [US/US]; 670 Almanor Avenue, Sunnyvale, CA 94086 (US).			
(72) Inventors: DRMANAC, Radoje, T.; 850 East Greenwich Place, Palo Alto, CA 94303 (US). CRKVENJAKOV, Radomir, 762 Haverhill Drive, Sunnyvale, CA 94087 (US). DICKSON, Mark; Apartment #B, 1411 Gabilan Drive, Hollister, CA 95023 (US). DRMANAC, Snezana; 850 East Greenwich Place, Palo Alto, CA 94303 (US). LABAT, Ivan; 1006 Ashbury Way, Mountain View, CA 94043 (US). LESHKOWITZ, Dena; 678 Durshire Way, Sunnyvale, CA 94087 (US). KITA, David; Apartment #204, 899 Bounty Drive, Foster City, CA 94404 (US). FORD, John; Apartment #402, 1380 Oak Creek Drive, Palo Alto, CA 94304 (US).			
(74) Agent: GRUPPI, Carol, M.; McCutchen, Doyle, Brown & Enersen, LLP, Three Embarcadero Center, San Francisco, CA 94111 (US).			<b>Published</b> <i>With international search report. Before the expiration of the time limit for amending the claims and to be republished in the event of the receipt of amendments.</i>

(54) Title: CHEMOKINE OBTAINED FROM A cDNA LIBRARY OF FETAL LIVER-SPLEEN

	10	20	30	40	50	60	70	
12616 protein	MOASRSLNPOHLS	SULVQLSKLGS	ROGAGGTGPRG	PLLEHAWQLP	RAGEGVTHCDY	KGNFKSPNLS	70	
MURRANTES	MCISAAAL	-----	TXILTAALCTP	APASF	-----	YGSDDTPCCF	44	
HUMLYMTC	MLLLILAL	-----	LGICSLTAYIV	EGVGE	-----	VSDKRT-CV	42	
	80	90	100	110	120	130	140	
12616 protein	CVKTAKPHYFNQ	CS-L-SVVTANG	NOCLONTT	-----	DFLAPPRPTES	SLQ	120	
MURRANTES	---AHVKEVPTTS	KCSL	---AVVPVTRR	NOVCANPEK	WQVEYI	-----	NYLE	90
HUMLYMTC	---SRIKTY	---TITEGS	---LRAVIFIT	IRGLKVCAD	QATWRDVV	-----	RSERKSNITQ	100
		150						
12616 protein	-----	VRSEVYF					126	
MURRANTES	-----	MS					91	
HUMLYMTC	-----	OTQOSINTAV	TLTG				114	

12616 protein:	Translated 12616 nucleotide sequence
MURRANTES:	Mouse RANTES
HUMLYMTC:	Human lymphotactin

(57) Abstract

The present invention provides polynucleotides and proteins encoded by such polynucleotides, along with therapeutic, diagnostic and research utilities for these polynucleotides and proteins. In particular, the polypeptides of the invention comprise amino acid sequences with similarity to chemokines.

**FOR THE PURPOSES OF INFORMATION ONLY**

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AL	Albania	ES	Spain	LS	Lesotho	SI	Slovenia
AM	Armenia	FI	Finland	LT	Lithuania	SK	Slovakia
AT	Austria	FR	France	LU	Luxembourg	SN	Senegal
AU	Australia	GA	Gabon	LV	Latvia	SZ	Swaziland
AZ	Azerbaijan	GB	United Kingdom	MC	Monaco	TD	Chad
BA	Bosnia and Herzegovina	GE	Georgia	MD	Republic of Moldova	TG	Togo
BB	Barbados	GH	Ghana	MG	Madagascar	TJ	Tajikistan
BE	Belgium	GN	Guinea	MK	The former Yugoslav Republic of Macedonia	TM	Turkmenistan
BF	Burkina Faso	GR	Greece			TR	Turkey
BG	Bulgaria	HU	Hungary	ML	Mali	TT	Trinidad and Tobago
BJ	Benin	IE	Ireland	MN	Mongolia	UA	Ukraine
BR	Brazil	IL	Israel	MR	Mauritania	UG	Uganda
BY	Belarus	IS	Iceland	MW	Malawi	US	United States of America
CA	Canada	IT	Italy	MX	Mexico	UZ	Uzbekistan
CF	Central African Republic	JP	Japan	NE	Niger	VN	Viet Nam
CG	Congo	KE	Kenya	NL	Netherlands	YU	Yugoslavia
CH	Switzerland	KG	Kyrgyzstan	NO	Norway	ZW	Zimbabwe
CI	Côte d'Ivoire	KP	Democratic People's Republic of Korea	NZ	New Zealand		
CM	Cameroon			PL	Poland		
CN	China	KR	Republic of Korea	PT	Portugal		
CU	Cuba	KZ	Kazakstan	RO	Romania		
CZ	Czech Republic	LC	Saint Lucia	RU	Russian Federation		
DE	Germany	LI	Liechtenstein	SD	Sudan		
DK	Denmark	LK	Sri Lanka	SE	Sweden		
EE	Estonia	LR	Liberia	SG	Singapore		

## CHEMOKINE OBTAINED FROM A CDNA LIBRARY OF FETAL LIVER-SPLEEN

5

**1. TECHNICAL FIELD**

The present invention provides novel polynucleotides and proteins encoded by such polynucleotides, along with therapeutic, diagnostic and research utilities for these polynucleotides and proteins.

10

**2. BACKGROUND ART**

Technology aimed at the discovery of protein factors (including e.g., cytokines, such as chemokines, lymphokines, interferons, CSFs and interleukins) has matured rapidly over the past decade. The now routine hybridization cloning and expression cloning techniques clone novel polynucleotides "directly" in the sense that they rely on information directly related to the discovered protein (i.e., partial DNA/amino acid sequence of the protein in the case of hybridization cloning; activity of the protein in the case of expression cloning). More recent "indirect" cloning techniques such as signal sequence cloning, which isolates DNA sequences based on the presence of a now well-recognized secretory leader sequence motif, as well as various PCR-based or low stringency hybridization cloning techniques, have advanced the state of the art by making available large numbers of DNA/amino acid sequences for proteins that are known to have biological activity by virtue of their secreted nature in the case of leader sequence cloning, or by virtue of the cell or tissue source in the case of PCR-based techniques. It is to these proteins and the polynucleotides encoding them that the present invention is directed. In particular, the invention is directed to a novel chemokine. The name "chemokine" is derived from the ability of these proteins to stimulate chemotaxis of leukocytes. Indeed, chemokines comprise the main attractants for inflammatory cells during inflammatory and immune responses. See generally, Baggiolini et al., *Advances in Immunology*, 55:97-179 (1994).

30

The chemokine superfamily represents a class of small cytokines that recruit a wide range of leukocytes to sites of infection, inflammation and disease. They have been shown

to be directly involved in the inflammatory process associated with conditions such as allergies (J Clin Invest 1997 Oct 1;100(7):1657-1666 Teixeira MM et al.), asthma (J Immunol 1997 Nov 1;159(9):4593-4601 Lamkhioed B, et al.), arthritis (J Exp Med 1997 Jul 7;186(1):131-137 Gong JH et al.), gastric inflammation (Physiol Pharmacol 1997 Sep; 48 (3):405-413 Watanabe N et al.), injury (Eur J Neurosci 1997 Jul;9(7):1422-1438 Bartholdi D, Schwab ME), transplantation rejection (Transplantation 1997 Jun 27;63(12):1807-1812 Fairchild RL et al.) autoimmune disorders (J Neuroimmunol 1997 Jul;77(1):17-26 Miyagishi R et al) and others. Chemokines generally exhibit 20-70% amino acid identity to each other and contain several highly-conserved cysteine residues. Chemokines can be classified into various subclasses or subfamilies by virtue of the position and spacing of a set of conserved cysteines, designated C-X-C (e.g. IL-8), C-C (e.g. RANTES) and C (e.g. lymphotactin). The C-X-C subfamily has the first two conserved cysteines separated by one amino acid, and the genes encoding the C-X-C subfamily are predominantly located on human chromosome 4. The C-C subfamily has two adjacent cysteines, and the genes encoding the C-C subfamily are predominantly located on human chromosome 17. The C subfamily has one of the first two conserved cysteines and the genes encoding the C subfamily are predominantly located on human chromosome 17.

### **3. DISCLOSURE OF THE INVENTION**

The compositions of the present invention include novel isolated polypeptides, in particular, novel chemokine polypeptides, isolated polynucleotides encoding such polypeptides, including recombinant DNA molecules, cloned genes or degenerate variants thereof, especially naturally occurring variants such as allelic variants, and antibodies that specifically recognize one or more epitopes present on such polypeptides.

The compositions of the present invention additionally include vectors, including expression vectors, containing the polynucleotides of the invention, cells genetically engineered to contain such polynucleotides and cells genetically engineered to express such polynucleotides.

The isolated polynucleotides of the invention include, but are not limited to, a

polynucleotide encoding a polypeptide comprising the amino acid sequence of SEQ ID  
5 NO: 3.

The isolated polynucleotides of the invention further include, but are not limited to  
a polynucleotide comprising the nucleotide sequence of SEQ ID NOS: 1 2, or nucleotides  
261-641 of SEQ ID NO: 2.

The polynucleotides of the present invention still further include, but are not  
10 limited to, a polynucleotide comprising the nucleotide sequence of the cDNA insert of  
clone p12616HY deposited with the American Type Culture Collection (ATCC; 10801  
University Blvd., Manassas, Virginia, 20110-2209, U.S.A.); a polynucleotide comprising a  
nucleotide sequence encoding a polypeptide comprising the amino acid sequence encoded  
by the cDNA insert of clone p12616HY; a polynucleotide comprising the full length  
15 protein coding sequence of SEQ ID NO: 3; a polynucleotide comprising the nucleotide  
sequence of the mature protein coding sequence of SEQ ID NO: 3.

The polynucleotides of the present invention also include, but are not limited to, a  
polynucleotide that hybridizes to the complement of the nucleotide sequence of SEQ ID  
NOS: 1, 2, or nucleotides 261-641 of SEQ ID NO:2 (the first nucleotide is designated as 1)  
20 under stringent hybridization conditions; a polynucleotide which is an allelic variant of  
any polynucleotide recited above; a polynucleotide which encodes a species homologue of  
any of the proteins recited above; or a polynucleotide that encodes a polypeptide  
comprising a specific domain or truncation of the polypeptide of SEQ ID NO: 3.

25 The polynucleotides of the invention additionally include the complement of any  
of the polynucleotides recited above.

The isolated polypeptides of the invention include, but are not limited to, a  
polypeptide comprising the amino acid sequence of SEQ ID NO:3.

The polypeptides of the present invention further include, but are not limited to, a  
30 polypeptide comprising the amino acid sequence encoded by the cDNA insert of clone  
p12616HY deposited with the American Type Culture Collection (ATCC; 10801  
University Blvd., Manassas, Virginia, 20110-2209, U.S.A.); a full length protein of SEQ  
ID NO:3 comprising the amino acid sequence encoded by the cDNA insert of clone

p12616HY, or a mature protein coding sequence of SEQ ID NO: 3 comprising the amino  
5 acid sequence encoded by cDNA insert of clone p12616HY.

Protein compositions of the present invention may further comprise an acceptable  
carrier, such as a hydrophilic, e.g., pharmaceutically acceptable, carrier.

The invention also relates to methods for producing a polypeptide comprising  
growing a culture of the cells of the invention in a suitable culture medium, and purifying  
10 the protein from the culture. Preferred embodiments include those in which the protein  
produced by such process is a mature form of the protein.

Polynucleotides according to the invention have numerous applications in a variety  
of techniques known to those skilled in the art of molecular biology. These techniques  
include use as hybridization probes, use as oligomers for PCR, use for chromosome and  
15 gene mapping, use in the recombinant production of protein, and use in generation of anti-  
sense DNA or RNA, their chemical analogs and the like. For example, when the  
expression of an mRNA is largely restricted to a particular cell or tissue type,  
polynucleotides of the invention can be used as hybridization probes to detect the presence  
of the particular cell or tissue mRNA in a sample using, e.g., in situ hybridization.  
20

In other exemplary embodiments, the polynucleotides are used in diagnostics as  
expressed sequence tags for identifying expressed genes or, as well known in the art and  
exemplified by Vollrath et al., Science 258:52-59 (1992), as expressed sequence tags for  
physical mapping of the human genome.

The polypeptides according to the invention can be used in a variety of  
25 conventional procedures and methods that are currently applied to other proteins. For  
example, a polypeptide of the invention can be used to generate an antibody that  
specifically binds the polypeptide. The polypeptides of the invention having ATPase  
activity are also useful for inhibiting platelet aggregation and can therefore be employed in  
30 the prophylaxis or treatment of pathological conditions caused by the inflammatory  
response. The polypeptides of the invention can also be used as molecular weight  
markers, and as a food supplement.

Methods are also provided for preventing, treating or ameliorating a medical

condition which comprises administering to a mammalian subject a therapeutically effective amount of a composition comprising a protein of the present invention and a pharmaceutically acceptable carrier.

In particular, the polypeptides and polynucleotides of the invention can be utilized, for example, as part of methods for modulation of the immune and inflammatory responses, and hematopoiesis. The polypeptides and polynucleotides of the invention may, therefore, be utilized, for example, as part of methods for treatment of allergies, autoimmune disorders, *e.g.* arthritis, transplantation rejection, tissue repair or wound healing, *e.g.*, treatment of surgical incisions, and ulcers, such as stomach or diabetic ulcers. In addition, the polynucleotides and polypeptides of the invention can further be utilized, for example, as part of methods for the prevention and/or treatment of disorders involving cell fate and differentiation, such as leukemias.

The methods of the present invention further relate to methods for detecting the presence of the polynucleotides or polypeptides of the invention in a sample. Such methods can, for example, be utilized as part of prognostic and diagnostic evaluation of disorders as recited above and for the identification of subjects exhibiting a predisposition to such conditions. Furthermore, the invention provides methods for evaluating the efficacy of drugs, and monitoring the progress of patients, involved in clinical trials for the treatment of disorders as recited above.

The invention also provides methods for the identification of compounds that modulate the expression of the polynucleotides and/or polypeptides of the invention. Such methods can be utilized, for example, for the identification of compounds that can ameliorate symptoms of disorders as recited above. Such methods can include, but are not limited to, assays for identifying compounds and other substances that interact with (*e.g.*, bind to) the polypeptides of the invention.

The methods of the invention also include methods for the treatment of disorders as recited above which may involve the administration of such compounds to individuals exhibiting symptoms or tendencies related to disorders as recited above. In addition, the invention encompasses methods for treating diseases or disorders as recited above by

administering compounds and other substances that modulate the overall activity of the  
 5 target gene products. Compounds and other substances can effect such modulation either  
 on the level of target gene expression or target protein activity.

#### 4. BRIEF DESCRIPTION OF THE DRAWINGS

FIG. 1 shows the sequence alignment of SEQ ID No. 3 with members of two  
 10 subfamilies of the chemokines. A- Alanine; R- Arginine; N- Asparagine; D- Aspartic Acid;  
 C- Cysteine; E- Glutamic Acid; Q- Glutamine; G- Glycine; H- Histidine; I- Isoleucine; L-  
 Leucine; K- Lysine; M- Methionine; F- Phenylalanine; P- Proline; S- Serine; T- Threonine;  
 W- Tryptophan; Y- Tyrosine; V- Valine; X - any of the twenty amino acids. Gaps are  
 presented as spaces and nonconserved residues as dashes. Regions of SEQ ID No. 3 are  
 15 labeled 12616. Mouse RANTES (MUSLYMTC) and Human Lymphotoxin (HUMLYMTC)  
 are labeled accordingly.

FIG. 2 shows the nucleic acid sequences that were obtained from the b<sup>2</sup>HFLS20W  
 cDNA library using standard pcr, sequencing by hybridization signature analysis, and single  
 20 pass gel sequencing technology. These sequences are designated as SEQ ID Nos. 1 and 2.  
 A- adenosine; C-cytosine; G-guanosine; T-thymidine; and N-any of the four bases.

FIG. 3 shows the amino acid sequences which correspond to the polynucleotide  
 sequences of SEQ ID No. 2. These sequences are designated as SEQ ID No. 3. A- Alanine;  
 R- Arginine; N- Asparagine; D- Aspartic Acid; C- Cysteine; E- Glutamic Acid; Q-  
 25 Glutamine; G- Glycine; H- Histidine; I- Isoleucine; L- Leucine; K- Lysine; M- Methionine;  
 F- Phenylalanine; P- Proline; S- Serine; T- Threonine; W- Tryptophan; Y- Tyrosine; V-  
 Valine; X - any of the twenty amino acids.

#### 5. MODES FOR CARRYING OUT THE INVENTION

30

##### 5.1. DEFINITIONS

The term "nucleotide sequence" refers to a heteropolymer of nucleotides or the  
 sequence of these nucleotides. The terms "nucleic acid" and "polynucleotide" are also  
 used interchangeably herein to refer to a heteropolymer of nucleotides. Generally, nucleic



acid segments provided by this invention may be assembled from fragments of the genome  
5 and short oligonucleotide linkers, or from a series of oligonucleotides, or from individual  
nucleotides, to provide a synthetic nucleic acid which is capable of being expressed in a  
recombinant transcriptional unit comprising regulatory elements derived from a microbial  
or viral operon, or a eukaryotic gene.

The terms "oligonucleotide fragment" or a "polynucleotide fragment", "portion," or  
10 "segment" is a stretch of polypeptide nucleotide residues which is long enough to use in  
polymerase chain reaction (PCR) or various hybridization procedures to identify or  
amplify identical or related parts of mRNA or DNA molecules.

The terms "oligonucleotides" or "nucleic acid probes" are prepared based on the  
polynucleotide sequences provided in the present invention. Oligonucleotides comprise  
15 portions of such a polynucleotide sequence having at least about 15 nucleotides and  
usually at least about 20 nucleotides. Nucleic acid probes comprise portions of such a  
polynucleotide sequence having fewer nucleotides than about 6 kb, usually fewer than  
about 1 kb. After appropriate testing to eliminate false positives, these probes may, for  
example, be used to determine whether specific mRNA molecules are present in a cell or  
20 tissue or to isolate similar nucleic acid sequences from chromosomal DNA as described by  
Walsh et al. (Walsh, P.S. et al., 1992, PCR Methods Appl 1:241-250).

The term "probes" includes naturally occurring or recombinant or chemically  
synthesized single- or double-stranded nucleic acids. They may be labeled by nick  
translation, Klenow fill-in reaction, PCR or other methods well known in the art. Probes  
25 of the present invention, their preparation and/or labeling are elaborated in Sambrook, J. et  
al., 1989, Molecular Cloning: A Laboratory Manual, Cold Spring Harbor Laboratory, NY;  
or Ausubel, F.M. et al., 1989, Current Protocols in Molecular Biology, John Wiley &  
Sons, New York NY, both of which are incorporated herein by reference in their entirety.

30 The term "stringent" is used to refer to conditions that are commonly understood in  
the art as stringent. Stringent conditions can include highly stringent conditions (*i.e.*,  
hybridization to filter-bound DNA under in 0.5 M NaHPO<sub>4</sub>, 7% sodium dodecyl sulfate  
(SDS), 1 mM EDTA at 65° C, and washing in 0.1xSSC/0.1% SDS at 68° C), and

moderately stringent conditions (*i.e.*, washing in 0.2xSSC/0.1% SDS at 42° C).

- 5 In instances wherein hybridization of deoxyoligonucleotides is concerned, additional exemplary stringent hybridization conditions include washing in 6xSSC/0.05% sodium pyrophosphate at 37°C (for 14-base oligos), 48°C (for 17-base oligos), 55°C (for 20-base oligos), and 60°C (for 23-base oligos).

- The term "recombinant," when used herein to refer to a polypeptide or protein, means that a polypeptide or protein is derived from recombinant (e.g., microbial or mammalian) expression systems. "Microbial" refers to recombinant polypeptides or proteins made in bacterial or fungal (e.g., yeast) expression systems. As a product, "recombinant microbial" defines a polypeptide or protein essentially free of native endogenous substances and unaccompanied by associated native glycosylation.
- 10 Polypeptides or proteins expressed in most bacterial cultures, e.g., *E. coli*, will be free of glycosylation modifications; polypeptides or proteins expressed in yeast will have a glycosylation pattern in general different from those expressed in mammalian cells.

- The term "recombinant expression vehicle or vector" refers to a plasmid or phage or virus or vector, for expressing a polypeptide from a DNA (RNA) sequence. An expression vehicle can comprise a transcriptional unit comprising an assembly of (1) a genetic element or elements having a regulatory role in gene expression, for example, promoters or enhancers, (2) a structural or coding sequence which is transcribed into mRNA and translated into protein, and (3) appropriate transcription initiation and termination sequences. Structural units intended for use in yeast or eukaryotic expression systems preferably include a leader sequence enabling extracellular secretion of translated protein by a host cell. Alternatively, where recombinant protein is expressed without a leader or transport sequence, it may include an N-terminal methionine residue. This residue may or may not be subsequently cleaved from the expressed recombinant protein
- 20 to provide a final product.

The term "recombinant expression system" means host cells which have stably integrated a recombinant transcriptional unit into chromosomal DNA or carry the recombinant transcriptional unit extrachromosomally. Recombinant expression systems as

defined herein will express heterologous polypeptides or proteins upon induction of the regulatory elements linked to the DNA segment or synthetic gene to be expressed. This term also means host cells which have stably integrated a recombinant genetic element or elements having a regulatory role in gene expression, for example, promoters or enhancers. Recombinant expression systems as defined herein will express polypeptides or proteins endogenous to the cell upon induction of the regulatory elements linked to the endogenous DNA segment or gene to be expressed. The cells can be prokaryotic or eukaryotic.

The term "open reading frame," ORF, means a series of nucleotide triplets coding for amino acids without any termination codons and is a sequence translatable into protein.

The term "expression modulating fragment," EMF, means a series of nucleotides which modulates the expression of an operably linked ORF or another EMF.

As used herein, a sequence is said to "modulate the expression of an operably linked sequence" when the expression of the sequence is altered by the presence of the EMF. EMFs include, but are not limited to, promoters, and promoter modulating sequences (inducible elements). One class of EMFs are fragments which induce the expression or an operably linked ORF in response to a specific regulatory factor or physiological event.

As used herein, an "uptake modulating fragment," UMF, means a series of nucleotides which mediate the uptake of a linked DNA fragment into a cell. UMFs can be readily identified using known UMFs as a target sequence or target motif with the computer-based systems described below.

The presence and activity of a UMF can be confirmed by attaching the suspected UMF to a marker sequence. The resulting nucleic acid molecule is then incubated with an appropriate host under appropriate conditions and the uptake of the marker sequence is determined. As described above, a UMF will increase the frequency of uptake of a linked marker sequence.

The term "active" refers to those forms of the polypeptide which retain the biologic and/or immunologic activities of any naturally occurring polypeptide.

The term "naturally occurring polypeptide" refers to polypeptides produced by  
5 cells that have not been genetically engineered and specifically contemplates various  
polypeptides arising from post-translational modifications of the polypeptide including,  
but not limited to, acetylation, carboxylation, glycosylation, phosphorylation, lipidation  
and acylation.

The term "derivative" refers to polypeptides chemically modified by such  
10 techniques as ubiquitination, labeling (e.g., with radionuclides or various enzymes),  
pegylation (derivatization with polyethylene glycol) and insertion or substitution by  
chemical synthesis of amino acids such as ornithine, which do not normally occur in  
human proteins.

The term "recombinant variant" refers to any polypeptide differing from naturally  
15 occurring polypeptides by amino acid insertions, deletions, and substitutions, created using  
recombinant DNA techniques. Guidance in determining which amino acid residues may  
be replaced, added or deleted without abolishing activities of interest, such as cellular  
trafficking, may be found by comparing the sequence of the particular polypeptide with  
that of homologous peptides and minimizing the number of amino acid sequence changes  
20 made in regions of high homology.

Preferably, amino acid "substitutions" are the result of replacing one amino acid  
with another amino acid having similar structural and/or chemical properties, i.e.,  
conservative amino acid replacements. Amino acid substitutions may be made on the  
25 basis of similarity in polarity, charge, solubility, hydrophobicity, hydrophilicity, and/or the  
amphipathic nature of the residues involved. For example, nonpolar (hydrophobic) amino  
acids include alanine, leucine, isoleucine, valine, proline, phenylalanine, tryptophan, and  
methionine; polar neutral amino acids include glycine, serine, threonine, cysteine, tyrosine,  
asparagine, and glutamine; positively charged (basic) amino acids include arginine, lysine,  
30 and histidine; and negatively charged (acidic) amino acids include aspartic acid and  
glutamic acid. "Insertions" or "deletions" are typically in the range of about 1 to 5 amino  
acids. The variation allowed may be experimentally determined by systematically making  
insertions, deletions, or substitutions of amino acids in a polypeptide molecule using

recombinant DNA techniques and assaying the resulting recombinant variants for activity.

5 Alternatively, where alteration of function is desired, insertions, deletions or non-conservative alterations can be engineered to produce altered polypeptides. Such alterations can, for example, alter one or more of the biological functions or biochemical characteristics of the polypeptides of the invention. For example, such alterations may change polypeptide characteristics such as ligand-binding affinities, interchain affinities,  
10 or degradation/turnover rate. Further, such alterations can be selected so as to generate polypeptides that are better suited for expression, scale up and the like in the host cells chosen for expression. For example, cysteine residues can be deleted or substituted with another amino acid residue in order to eliminate disulfide bridges.

As used herein, "substantially equivalent" can refer both to nucleotide and amino  
15 acid sequences, for example a mutant sequence, that varies from a reference sequence by one or more substitutions, deletions, or additions, the net effect of which does not result in an adverse functional dissimilarity between the reference and subject sequences.

Typically, such a substantially equivalent sequence varies from one of those listed herein by no more than about 20% (i.e., the number of individual residue substitutions, additions,  
20 and/or deletions in a substantially equivalent sequence, as compared to the corresponding reference sequence, divided by the total number of residues in the substantially equivalent sequence is about 0.2 or less). Such a sequence is said to have 80% sequence identity to the listed sequence. In one embodiment, a substantially equivalent, e.g., mutant, sequence  
25 of the invention varies from a listed sequence by no more than 10% (90% sequence identity); in a variation of this embodiment, by no more than 5% (95% sequence identity); and in a further variation of this embodiment, by no more than 2% (98% sequence identity). Substantially equivalent, e.g., mutant, amino acid sequences according to the invention generally have at least 95% sequence identity with a listed amino acid sequence,  
30 whereas substantially equivalent nucleotide sequence of the invention can have lower percent sequence identities, taking into account, for example, the redundancy or degeneracy of the genetic code. For the purposes of the present invention, sequences having substantially equivalent biological activity and substantially equivalent expression

characteristics are considered substantially equivalent. For the purposes of determining equivalence, truncation of the mature sequence (*e.g.*, via a mutation which creates a  
5 spurious stop codon) should be disregarded.

Nucleic acid sequences encoding such substantially equivalent sequences, *e.g.*, sequences of the recited percent identities, can routinely be isolated and identified via standard hybridization procedures well known to those of skill in the art.

10 Where desired, an expression vector may be designed to contain a "signal or leader sequence" which will direct the polypeptide through the membrane of a cell. Such a sequence may be naturally present on the polypeptides of the present invention or provided from heterologous protein sources by recombinant DNA techniques.

A polypeptide "fragment," "portion," or "segment" is a stretch of amino acid  
15 residues of at least about 5 amino acids, often at least about 7 amino acids, typically at least about 9 to 13 amino acids, and, in various embodiments, at least about 17 or more amino acids. To be active, any polypeptide must have sufficient length to display biologic and/or immunologic activity.

Alternatively, recombinant variants encoding these same or similar polypeptides  
20 may be synthesized or selected by making use of the "redundancy" in the genetic code. Various codon substitutions, such as the silent changes which produce various restriction sites, may be introduced to optimize cloning into a plasmid or viral vector or expression in a particular prokaryotic or eukaryotic system. Mutations in the polynucleotide sequence  
25 may be reflected in the polypeptide or domains of other peptides added to the polypeptide to modify the properties of any part of the polypeptide, to change characteristics such as ligand-binding affinities, interchain affinities, or degradation/turnover rate.

The term "activated" cells as used in this application are those which are engaged in extracellular or intracellular membrane trafficking, including the export of  
30 neurosecretory or enzymatic molecules as part of a normal or disease process.

The term "purified" as used herein denotes that the indicated nucleic acid or polypeptide is present in the substantial absence of other biological macromolecules, *e.g.*, polynucleotides, proteins, and the like. In one embodiment, the polynucleotide or

polypeptide is purified such that it constitutes at least 95% by weight, more preferably at least 99.8% by weight, of the indicated biological macromolecules present (but water, buffers, and other small molecules, especially molecules having a molecular weight of less than 1000 daltons, can be present).

The term "isolated" as used herein refers to a nucleic acid or polypeptide separated from at least one other component (e.g., nucleic acid or polypeptide) present with the nucleic acid or polypeptide in its natural source. In one embodiment, the nucleic acid or polypeptide is found in the presence of (if anything) only a solvent, buffer, ion, or other component normally present in a solution of the same. The terms "isolated" and "purified" do not encompass nucleic acids or polypeptides present in their natural source.

The term "infection" refers to the introduction of nucleic acids into a suitable host cell by use of a virus or viral vector.

The term "transformation" means introducing DNA into a suitable host cell so that the DNA is replicable, either as an extrachromosomal element, or by chromosomal integration.

The term "transfection" refers to the taking up of an expression vector by a suitable host cell, whether or not any coding sequences are in fact expressed.

The term "intermediate fragment" means a nucleic acid between 5 and 1000 bases in length, and preferably between 10 and 40 bp in length.

The term "secreted" protein includes a protein that is transported across or through a membrane, including transport as a result of signal sequences in its amino acid sequence when it is expressed in a suitable host cell. "Secreted" proteins also includes without limitation proteins secreted wholly (e.g., soluble proteins) or partially (e.g., receptors) from the cell in which they are expressed. "Secreted" proteins also include without limitation proteins which are transported across the membrane of the endoplasmic reticulum. "Secreted" proteins are also intended to include proteins containing non-typical signal sequences (e.g. Interleukin-1 *Beta*, see Krasney, P.A. and Young, P.R. (1992) *Cytokine* 4(2): 134 -143) and factors released from damaged cells (e.g. Interleukin-1 Receptor Antagonist, see Arend, W.P. et. al. (1998) *Annu. Rev. Immunol.* 16:27-55)

Each of the above terms is meant to encompass all that is described for each,  
5 unless the context dictates otherwise.

### **POLYNUCLEOTIDES AND NUCLEIC ACIDS OF THE INVENTION**

Nucleotide and amino acid sequences of the invention are reported below.

Fragments of the proteins of the present invention which are capable of exhibiting  
10 biological activity are also encompassed by the present invention. Fragments of the protein  
may be in linear form or they may be cyclized using known methods, for example, as  
described in H. U. Saragovi, et al., Bio/Technology 10, 773-778 (1992) and in R. S.  
McDowell, et al., J. Amer. Chem. Soc. 114, 9245-9253 (1992), both of which are  
incorporated herein by reference. Such fragments may be fused to carrier molecules such  
15 as immunoglobulins for many purposes, including increasing the valency of protein  
binding sites. For example, fragments of the protein may be fused through "linker"  
sequences to the Fc portion of an immunoglobulin. For a bivalent form of the protein, such  
a fusion could be to the Fc portion of an IgG molecule. Other immunoglobulin isotypes  
may also be used to generate such fusions. For example, a protein-IgM fusion would  
20 generate a decavalent form of the protein of the invention.

The present invention also provides both full-length and mature forms (*e.g.* without  
a signal sequence) of the disclosed proteins. The full-length form of the such proteins is  
identified in the sequence listing by translation of the nucleotide sequence of each  
25 disclosed clone. The mature form of such protein may be obtained by expression of the  
disclosed full-length polynucleotide (for example, obtained from using the clones  
deposited with ATCC using standard techniques) in a suitable mammalian cell or other  
host cell. The sequence of the mature form of the protein is also determinable from the  
amino acid sequence of the full-length form.

30 The present invention also provides genes corresponding to the cDNA sequences  
disclosed herein. The corresponding genes can be isolated in accordance with known  
methods using the sequence information disclosed herein. Such methods include the  
preparation of probes or primers from the disclosed sequence information for identification



and/or amplification of genes in appropriate genomic libraries or other sources of genomic materials.

Where the protein of the present invention is membrane-bound the present invention also provides for soluble forms of such protein. In such forms part or all of the domains of the protein causing the protein to be membrane bound are deleted such that the protein is fully secreted from the cell in which it is expressed.

Species homologs of the disclosed polynucleotides and proteins are also provided by the present invention. Species homologs may be isolated and identified by making suitable probes or primers from the sequences provided herein and screening a suitable nucleic acid source from the desired species.

The invention also encompasses allelic variants of the disclosed polynucleotides or proteins; that is, naturally-occurring alternative forms of the isolated polynucleotide which also encode proteins which are identical, homologous or related to that encoded by the polynucleotides.

The compositions of the present invention include isolated polynucleotides, including recombinant DNA molecules, cloned genes or degenerate variants thereof, especially naturally occurring variants such as allelic variants, novel isolated polypeptides, and antibodies that specifically recognize one or more epitopes present on such polypeptides.

Species homologs of the disclosed polynucleotides and proteins are also provided by the present invention. Species homologs may be isolated and identified by making suitable probes or primers from the sequences provided herein and screening a suitable nucleic acid source from the desired species.

The invention also encompasses allelic variants of the disclosed polynucleotides or proteins; that is, naturally-occurring alternative forms of the isolated polynucleotide which also encode proteins which are identical, homologous or related to that encoded by the polynucleotides.

## **5.2. NUCLEIC ACIDS OF THE INVENTION**

SEQ ID No. 2 encodes the polypeptide sequence of SEQ ID No. 3. In  
5 general, the content and position of certain highly conserved amino acid residues identifies  
SEQ ID No. 3 as a member of the chemokine family. Figure 1 presents an alignment of CC  
and C types of chemokines. SEQ ID No. 3 has features common to both types but has  
differences significant enough to classify it as a new subfamily type. While SEQ ID No. 3  
has only a C motif in the first cysteine position, it has a total of four conserved cysteines, a  
10 feature found only in the CC and CXC subtypes. It has most homology to the RANTES  
chemokine, but has three insertions not found in RANTES nor in the lymphotactin sequences  
(see Figure 1). SEQ ID No. 2 represents a novel subtype of chemokine, with features of both  
C and CC types of chemokines. A BLAST search revealed that SEQ ID No. 2 has  
significant homology (greater than 70% identity over a 100 nucleotide stretch) with a  
15 genomic fragment of chromosome 17. This provides evidence that SEQ ID No. 2 and  
possibly other subfamily members are situated on this chromosome. Since both the C and  
CC subtypes of chemokines are located on the same chromosome, perhaps this novel  
chemokine is physically linked to two of the other subtypes of chemokines. A start codon is  
located at nucleotides 261-263 of SEQ ID NO: 2 and a stop codon at nucleotides 639-641 of  
20 SEQ ID NO: 2

Chemokines have been shown to be directly involved in the inflammatory process  
associated with conditions such as allergies (J Clin Invest 1997 Oct 1;100(7):1657-1666  
Teixeira MM et al.), asthma (J Immunol 1997 Nov 1;159(9):4593-4601 Lamkhioed B, et  
25 al.), arthritis (J Exp Med 1997 Jul 7;186(1):131-137 Gong JH et al.), gastric inflammation  
(Physiol Pharmacol 1997 Sep; 48 (3):405-413 Watanabe N et al.), injury (Eur J Neurosci  
1997 Jul;9(7):1422-1438 Bartholdi D, Schwab ME), transplantation rejection  
(Transplantation 1997 Jun 27;63(12):1807-1812 Fairchild RL et al.) autoimmune disorders  
(J Neuroimmunol 1997 Jul;77(1):17-26 Miyagishi R et al) and others. Chemokines are  
30 potent stimulants of neutrophils causing rapid shape change, chemotaxis, respiratory bursts,  
and degranulation. Chemokines are also known to be potent chemoattractants for a variety  
of blood cell components, including monocytes, eosinophils, and T-lymphocytes.

Chemokines have also been used in medical imaging, e.g., for imaging the site of infection, inflammation, and other sites having chemokine receptor molecules. Additionally, the established correlation between chemokine expression and inflammatory conditions and disease states provides diagnostic and prognostic indications for the use of chemokines. Chemokines promote the healing of wounds and/or the speed of recovery from conditions where inflammation is important to eradication of infection, such as, for example, pneumonia. Conversely, inhibition of inflammation is important in pathological conditions caused by the inflammatory response. The novel chemokines of the invention will facilitate the diagnosis and prognosis of these indications, and the modulation of the inflammatory and immune responses. One example of this is found, for e.g., in a report by Gong *et al.*, J. Exp. Med. 186:131-137 (1997), where agonists to a chemokine (MCP-1) were used to inhibit arthritis in a mouse model system.

The chemokines of the invention are also useful for making antibody substances that are specifically immunoreactive with chemokines. Antibodies and other small molecules which bind to the chemokines of the invention can act as blocking agents, or as activators.

Chemokines have also been shown to regulate proliferation and/or differentiation of hematopoietic stem and progenitor cells *in vitro* and *in vivo*. Thus, the novel chemokines of the invention are useful in methods of treating neutropenia caused by, for example, chemotherapy-or radiation treatments. The novel chemokines of the invention are also useful in new methods for screening and treating patients with certain myelogenous leukemias as well as other hyperproliferative blood diseases. In addition, the novel chemokines can be used to identify, purify, and expand progenitor-specific cell populations in an *ex vivo* setting for re-introduction into a patient following radiation or chemotherapy.

The subclass of progenitor cells that respond to the presence of chemokines has been shown to include a cell population which contains the cell surface marker CD34. Therefore, the novel chemokine polypeptides can be used as diagnostic agents to identify CD34 + progenitor cells in a sample population. For example, a solid substrate or matrix coated with a novel chemokine polypeptide can be used to separate out cells that are responsive to the protein from a sample of cells removed from a patient. After culturing or expansion of these

CD34 + cells ex vivo, these cells can be re-introduced into the patient following transplant,  
5 chemotherapy, or radiation therapy.

The novel chemokine polypeptides of the invention can be administered as  
adjunctive agents before and/or during chemotherapy or radiation therapy to protect myeloid  
progenitor cells from the cytotoxic effects of the chemotherapeutic agents or radiation. The  
novel proteins place myeloid cells into a myeloprotected, slow-cycling state, thereby  
10 inhibiting or decreasing cell damage that could otherwise be caused by cell-cycle active  
chemotherapy drugs such as cytosine arabinoside, 5-fluorouracil, or hydroxyurea. The use of  
the novel proteins also permits the administration of higher doses of chemotherapeutics  
without compromising the ability of the patient to generate mature functional blood cells.

*In vivo* murine studies with IL-8M1 have shown that effective suppression of  
15 progenitor cell proliferation occurs at dosages of approximately 10.0 to 0.01  $\mu\text{g}$  per  
animal, although 1.0 to 0.01  $\mu\text{g}$  per animal is preferred. This translates into a dosage of  
approximately 0.5 to 500  $\mu\text{g}/\text{kg}$ . Assuming the average human patient weighs 70 kgs, the  
effective amount for a human would be approximately 0.035 to 35.0 mg. Thus, a suitable  
dosage for therapy in a human patient would be in the range of about 0.035 to 35.0 mg, with  
20 a preferred range of about 0.5 to 5 mg.

The novel chemokine polypeptides are useful for inhibiting hyperproliferative  
myeloid based diseases such as chronic myelogenous leukemia, polycythemia vera, and  
hypermegakaryocytopoietic disorders. Hyperproliferative states in such disorders occur  
because the progenitor cells are unable to negatively regulate cell growth and replication.  
25 Administration of the novel chemokine polypeptides inhibits cell replication resulting in the  
inhibition of the abnormal cell growth. Dosages of chemokine polypeptides for treating  
hyperproliferative myeloid based diseases would be similar to those dosages described above  
for use of the proteins as adjuncts to chemotherapy.

30 In addition, the novel chemokine polypeptides also can be used to prevent myeloid  
progenitor cells from becoming leukemic as the result of the administration of  
chemotherapeutic agents. The chemokine polypeptides are administered in the same way  
described above.

The isolated polynucleotides of the invention include, but are not limited to  
5 polynucleotides encoding a polypeptide comprising the amino acid sequence of SEQ ID  
NO:3 as well as polynucleotides which encode specific domains thereof.

In particular embodiments, the isolated polynucleotides of the invention include,  
but are not limited to, a polynucleotide comprising the nucleotide sequence of SEQ ID  
NO:1, 2 or nucleotides 261-641 of SEQ ID NO: 2.

10 The polynucleotides of the present invention still further include, but are not  
limited to, a polynucleotide comprising the nucleotide sequence of the cDNA insert of  
clone p12616HY; a polynucleotide comprising the nucleotide sequence encoding a  
polypeptide comprising the amino acid sequence encoded by the cDNA insert of clone  
p12616HY; a polynucleotide comprising the full length protein coding sequence of SEQ  
15 ID NO: 3 which polynucleotide comprises the cDNA insert of clone p12616HY, or; a  
polynucleotide comprising the nucleotide sequence of the mature protein coding sequence  
of SEQ ID NO: 3 which polynucleotide comprises the cDNA insert of clone p12616HY.

The polynucleotides of the present invention also include, but are not limited to, a  
polynucleotide that hybridizes to the complement of the nucleotide sequence of SEQ ID  
20 NOS:1,2 or nucleotides 261-641 of SEQ ID NO: 2 under stringent hybridization  
conditions; a polynucleotide which is an allelic variant of any polynucleotide recited  
above; a polynucleotide which encodes a species homologue of any of the proteins recited  
above; or a polynucleotide that encodes a polypeptide comprising an additional specific  
25 domain or truncation of the polypeptide of SEQ ID NO: 3.

The polynucleotides of the invention additionally include the complement of any  
of the polynucleotides recited above.

The polynucleotides of the invention also provide polynucleotides including  
nucleotide sequences that are substantially equivalent to the polynucleotides recited above.  
30 Polynucleotides according to the invention can have at least about 80%, more typically at  
least about 90%, and even more typically at least about 95%, sequence identity to a  
polynucleotide recited above. The invention also provides the complement of the  
polynucleotides including a nucleotide sequence that has at least about 80%, more

typically at least about 90%, and even more typically at least about 95%, sequence identity to a polynucleotide encoding a polypeptide recited above. The polynucleotide can be DNA  
5 (genomic, cDNA, amplified, or synthetic) or RNA. Methods and algorithms for obtaining such polynucleotides are well known to those of skill in the art and can include, for example, methods for determining hybridization conditions which can routinely isolate polynucleotides of the desired sequence identities.

10 A polynucleotide according to the invention can be joined to any of a variety of other nucleotide sequences by well-established recombinant DNA techniques (see Sambrook J et al. (1989) Molecular Cloning: A Laboratory Manual, Cold Spring Harbor Laboratory, NY). Useful nucleotide sequences for joining to polypeptides include an assortment of vectors, e.g., plasmids, cosmids, lambda phage derivatives, phagemids, and  
15 the like, that are well known in the art. Accordingly, the invention also provides a vector including a polynucleotide of the invention and a host cell containing the polynucleotide. In general, the vector contains an origin of replication functional in at least one organism, convenient restriction endonuclease sites, and a selectable marker for the host cell. Vectors according to the invention include expression vectors, replication vectors, probe  
20 generation vectors, and sequencing vectors. A host cell according to the invention can be a prokaryotic or eukaryotic cell and can be a unicellular organism or part of a multicellular organism.

The sequences falling within the scope of the present invention are not limited to  
25 the specific sequences herein described, but also include allelic variations thereof. Allelic variations can be routinely determined by comparing the sequence provided in SEQ ID NOS: 1, 2 or nucleotides 261-641 of SEQ ID NO: 2, a representative fragment thereof, or a nucleotide sequence at least 99.9% identical to SEQ ID NOS: 1, 2 or nucleotides 261-641 of SEQ ID NO: 2, with a sequence from another isolate of the same species. Furthermore,  
30 to accommodate codon variability, the invention includes nucleic acid molecules coding for the same amino acid sequences as do the specific ORFs disclosed herein. In other words, in the coding region of an ORF, substitution of one codon for another which encodes the same amino acid is expressly contemplated. Any specific sequence disclosed

herein can be readily screened for errors by resequencing a particular fragment, such as an ORF, in both directions (i.e., sequence both strands).

The present invention further provides recombinant constructs comprising a nucleic acid having the sequence of SEQ ID NOS:1, 2 or nucleotides 261 - 641 of SEQ ID NO: 2, or a fragment thereof. The recombinant constructs of the present invention comprise a vector, such as a plasmid or viral vector, into which a nucleic acid having the sequence of SEQ ID NOS:1, 2 or nucleotides 261 - 641 of SEQ ID NO: 2, or a fragment thereof is inserted, in a forward or reverse orientation. In the case of a vector comprising one of the ORFs of the present invention, the vector may further comprise regulatory sequences, including for example, a promoter, operably linked to the ORF. For vectors comprising the EMFs and UMFs of the present invention, the vector may further comprise a marker sequence or heterologous ORF operably linked to the EMF or UMF. Large numbers of suitable vectors and promoters are known to those of skill in the art and are commercially available for generating the recombinant constructs of the present invention.

The following vectors are provided by way of example. Bacterial: pBs, phagescript, PsiX174, pBluescript SK, pBs KS, pNH8a, pNH16a, pNH18a, pNH46a (Stratagene); pTrc99A, pKK223-3, pKK233-3, pDR540, pRIT5 (Pharmacia). Eukaryotic: pWLneo, pSV2cat, pOG44, PXTI, pSG (Stratagene) pSVK3, pBPV, pMSG, pSVL (Pharmacia).

The isolated polynucleotide of the invention may be operably linked to an expression control sequence such as the pMT2 or pED expression vectors disclosed in Kaufman et al., Nucleic Acids Res. 19, 4485-4490 (1991), in order to produce the protein recombinantly. Many suitable expression control sequences are known in the art. General methods of expressing recombinant proteins are also known and are exemplified in R. Kaufman, Methods in Enzymology 185, 537-566 (1990). As defined herein "operably linked" means that the isolated polynucleotide of the invention and an expression control sequence are situated within a vector or cell in such a way that the protein is expressed by a host cell which has been transformed (transfected) with the ligated polynucleotide/expression control sequence.

Promoter regions can be selected from any desired gene using CAT

(chloramphenicol transferase) vectors or other vectors with selectable markers. Two  
5 appropriate vectors are pKK232-8 and pCM7. Particular named bacterial promoters  
include lacI, lacZ, T3, T7, gpt, lambda P<sub>R</sub>, and trc. Eukaryotic promoters include CMV  
immediate early, HSV thymidine kinase, early and late SV40, LTRs from retrovirus, and  
mouse metallothionein-I. Selection of the appropriate vector and promoter is well within  
the level of ordinary skill in the art. Generally, recombinant expression vectors will  
10 include origins of replication and selectable markers permitting transformation of the host  
cell, e.g., the ampicillin resistance gene of *E. coli* and *S. cerevisiae* TRP1 gene, and a  
promoter derived from a highly-expressed gene to direct transcription of a downstream  
structural sequence. Such promoters can be derived from operons encoding glycolytic  
enzymes such as 3-phosphoglycerate kinase (PGK), a-factor, acid phosphatase, or heat  
15 shock proteins, among others. The heterologous structural sequence is assembled in  
appropriate phase with translation initiation and termination sequences, and preferably, a  
leader sequence capable of directing secretion of translated protein into the periplasmic  
space or extracellular medium. Optionally, the heterologous sequence can encode a fusion  
protein including an N-terminal identification peptide imparting desired characteristics,  
20 e.g., stabilization or simplified purification of expressed recombinant product. Useful  
expression vectors for bacterial use are constructed by inserting a structural DNA sequence  
encoding a desired protein together with suitable translation initiation and termination  
signals in operable reading phase with a functional promoter. The vector will comprise  
25 one or more phenotypic selectable markers and an origin of replication to ensure  
maintenance of the vector and to, if desirable, provide amplification within the host.  
Suitable prokaryotic hosts for transformation include *E. coli*, *Bacillus subtilis*, *Salmonella*  
*typhimurium* and various species within the genera *Pseudomonas*, *Streptomyces*, and  
*Staphylococcus*, although others may also be employed as a matter of choice.

30 As a representative but non-limiting example, useful expression vectors for  
bacterial use can comprise a selectable marker and bacterial origin of replication derived  
from commercially available plasmids comprising genetic elements of the well known  
cloning vector pBR322 (ATCC 37017). Such commercial vectors include, for example,



pKK223-3 (Pharmacia Fine Chemicals, Uppsala, Sweden) and GEM 1 (Promega Biotec,  
5 Madison, WI, USA). These pBR322 "backbone" sections are combined with an  
appropriate promoter and the structural sequence to be expressed. Following  
transformation of a suitable host strain and growth of the host strain to an appropriate cell  
density, the selected promoter is induced or derepressed by appropriate means (e.g.,  
temperature shift or chemical induction) and cells are cultured for an additional period.  
10 Cells are typically harvested by centrifugation, disrupted by physical or chemical means,  
and the resulting crude extract retained for further purification.

Included within the scope of the nucleic acid sequences of the invention are nucleic  
acid sequences that hybridize under stringent conditions to a fragment of the DNA  
sequences in Figure 2 or its complement, which fragment is greater than about 10 bp,  
15 preferably 20-50 bp, and even greater than 100 bp. In accordance with the invention,  
polynucleotide sequences which encode the novel nucleic acids, or functional equivalents  
thereof, may be used to generate recombinant DNA molecules that direct the expression of  
that nucleic acid, or a functional equivalent thereof, in appropriate host cells.

20 The nucleic acid sequences of the invention are further directed to sequences which  
encode variants of the described nucleic acids. These amino acid sequence variants may  
be prepared by methods known in the art by introducing appropriate nucleotide changes  
into a native or variant polynucleotide. There are two variables in the construction of  
amino acid sequence variants: the location of the mutation and the nature of the mutation.

25 The amino acid sequence variants of the nucleic acids are preferably constructed by  
mutating the polynucleotide to give an amino acid sequence that does not occur in nature.  
These amino acid alterations can be made at sites that differ in the nucleic acids from  
different species (variable positions) or in highly conserved regions (constant regions).  
Sites at such locations will typically be modified in series, e.g., by substituting first with  
30 conservative choices (e.g., hydrophobic amino acid to a different hydrophobic amino acid)  
and then with more distant choices (e.g., hydrophobic amino acid to a charged amino  
acid), and then deletions or insertions may be made at the target site. Amino acid  
sequence deletions generally range from about 1 to 30 residues, preferably about 1 to 10

residues, and are typically contiguous. Amino acid insertions include amino- and/or  
5 carboxyl-terminal fusions ranging in length from one to one hundred or more residues, as  
well as intrasequence insertions of single or multiple amino acid residues. Intrasequence  
insertions may range generally from about 1 to 10 amino residues, preferably from 1 to 5  
residues. Examples of terminal insertions include the heterologous signal sequences  
necessary for secretion or for intracellular targeting in different host cells.

10 In a preferred method, polynucleotides encoding the novel nucleic acids are  
changed via site-directed mutagenesis. This method uses oligonucleotide sequences that  
encode the polynucleotide sequence of the desired amino acid variant, as well as a  
sufficient adjacent nucleotide on both sides of the changed amino acid to form a stable  
duplex on either side of the site of being changed. In general, the techniques of site-  
15 directed mutagenesis are well known to those of skill in the art and this technique is  
exemplified by publications such as, Edelman *et al.*, DNA 2:183 (1983). A versatile and  
efficient method for producing site-specific changes in a polynucleotide sequence was  
published by Zoller and Smith, Nucleic Acids Res. 10:6487-6500 (1982). PCR may also  
be used to create amino acid sequence variants of the novel nucleic acids. When small  
20 amounts of template DNA are used as starting material, primer(s) that differs slightly in  
sequence from the corresponding region in the template DNA can generate the desired  
amino acid variant. PCR amplification results in a population of product DNA fragments  
that differ from the polynucleotide template encoding the polypeptide at the position  
specified by the primer. The product DNA fragments replace the corresponding region in  
25 the plasmid and this gives the desired amino acid variant.

A further technique for generating amino acid variants is the cassette mutagenesis  
technique described in Wells *et al.*, Gene 34:315 (1985); and other mutagenesis techniques  
well known in the art, such as, for example, the techniques in Sambrook *et al.*, supra, and  
30 Current Protocols in Molecular Biology, Ausubel *et al.* Due to the inherent degeneracy of  
the genetic code, other DNA sequences which encode substantially the same or a  
functionally equivalent amino acid sequence may be used in the practice of the invention  
for the cloning and expression of these novel nucleic acids. Such DNA sequences include

those which are capable of hybridizing to the appropriate novel nucleic acid sequence  
5 under stringent conditions.

### 5.3. HOSTS

The present invention further provides host cells genetically engineered to contain the polynucleotides of the invention. For example, such host cells may contain nucleic  
10 acids of the invention introduced into the host cell using known transformation, transfection or infection methods. The present invention still further provides host cells genetically engineered to express the polynucleotides of the invention, wherein such polynucleotides are in operative association with a regulatory sequence heterologous to the host cell which drives expression of the polynucleotides in the cell.

15 The host cell can be a higher eukaryotic host cell, such as a mammalian cell, a lower eukaryotic host cell, such as a yeast cell, or the host cell can be a prokaryotic cell, such as a bacterial cell. Introduction of the recombinant construct into the host cell can be effected by calcium phosphate transfection, DEAE, dextran mediated transfection, or electroporation (Davis, L. *et al.*, *Basic Methods in Molecular Biology* (1986)). The host  
20 cells containing one of polynucleotides of the invention, can be used in conventional manners to produce the gene product encoded by the isolated fragment (in the case of an ORF) or can be used to produce a heterologous protein under the control of the EMF.

Any host/vector system can be used to express one or more of the ORFs of the  
25 present invention. These include, but are not limited to, eukaryotic hosts such as HeLa cells, Cv-1 cell, COS cells, and Sf9 cells, as well as prokaryotic host such as *E. coli* and *B. subtilis*. The most preferred cells are those which do not normally express the particular polypeptide or protein or which expresses the polypeptide or protein at low natural level. Mature proteins can be expressed in mammalian cells, yeast, bacteria, or other cells under  
30 the control of appropriate promoters. Cell-free translation systems can also be employed to produce such proteins using RNAs derived from the DNA constructs of the present invention. Appropriate cloning and expression vectors for use with prokaryotic and eukaryotic hosts are described by Sambrook, *et al.*, in *Molecular Cloning: A Laboratory*

*Manual*, Second Edition, Cold Spring Harbor, New York (1989), the disclosure of which is hereby incorporated by reference.

5 Various mammalian cell culture systems can also be employed to express recombinant protein. Examples of mammalian expression systems include the COS-7 lines of monkey kidney fibroblasts, described by Gluzman, *Cell* 23:175 (1981), and other cell lines capable of expressing a compatible vector, for example, the C127, 3T3, CHO, 10 HeLa and BHK cell lines. Mammalian expression vectors will comprise an origin of replication, a suitable promoter and also any necessary ribosome binding sites, polyadenylation site, splice donor and acceptor sites, transcriptional termination sequences, and 5' flanking nontranscribed sequences. DNA sequences derived from the SV40 viral genome, for example, SV40 origin, early promoter, enhancer, splice, and 15 polyadenylation sites may be used to provide the required nontranscribed genetic elements. Recombinant polypeptides and proteins produced in bacterial culture are usually isolated by initial extraction from cell pellets, followed by one or more salting-out, aqueous ion exchange or size exclusion chromatography steps. Protein refolding steps can be used, as necessary, in completing configuration of the mature protein. Finally, high 20 performance liquid chromatography (HPLC) can be employed for final purification steps. Microbial cells employed in expression of proteins can be disrupted by any convenient method, including freeze-thaw cycling, sonication, mechanical disruption, or use of cell lysing agents.

25 A number of types of cells may act as suitable host cells for expression of the protein. Mammalian host cells include, for example, monkey COS cells, Chinese Hamster Ovary (CHO) cells, human kidney 293 cells, human epidermal A431 cells, human Colo205 cells, 3T3 cells, CV-1 cells, other transformed primate cell lines, normal diploid cells, cell strains derived from in vitro culture of primary tissue, primary explants, HeLa 30 cells, mouse L cells, BHK, HL-60, U937, HaK or Jurkat cells.

Alternatively, it may be possible to produce the protein in lower eukaryotes such as yeast or in prokaryotes such as bacteria. Potentially suitable yeast strains include *Saccharomyces cerevisiae*, *Schizosaccharomyces pombe*, *Kluyveromyces* strains, *Candida*,

or any yeast strain capable of expressing heterologous proteins. Potentially suitable  
5 bacterial strains include *Escherichia coli*, *Bacillus subtilis*, *Salmonella typhimurium*, or  
any bacterial strain capable of expressing heterologous proteins. If the protein is made in  
yeast or bacteria, it may be necessary to modify the protein produced therein, for example  
by phosphorylation or glycosylation of the appropriate sites, in order to obtain the  
functional protein. Such covalent attachments may be accomplished using known chemical  
10 or enzymatic methods.

In another embodiment of the present invention, cells and tissues may be  
engineered to express an endogenous gene comprising the polynucleotides of the invention  
under the control of inducible regulatory elements, in which case the regulatory sequences  
of the endogenous gene may be replaced by homologous recombination. As described  
15 herein, gene targeting can be used to replace a gene's existing regulatory region with a  
regulatory sequence isolated from a different gene or a novel regulatory sequence  
synthesized by genetic engineering methods. Such regulatory sequences may be  
comprised of promoters, enhancers, scaffold-attachment regions, negative regulatory  
elements, transcriptional initiation sites, regulatory protein binding sites or combinations  
20 of said sequences. Alternatively, sequences which affect the structure or stability of the  
RNA or protein produced may be replaced, removed, added, or otherwise modified by  
targeting, including polyadenylation signals. mRNA stability elements, splice sites, leader  
sequences for enhancing or modifying transport or secretion properties of the protein, or  
other sequences which alter or improve the function or stability of protein or RNA  
25 molecules.

The targeting event may be a simple insertion of the regulatory sequence, placing  
the gene under the control of the new regulatory sequence, e.g., inserting a new promoter  
or enhancer or both upstream of a gene. Alternatively, the targeting event may be a simple  
30 deletion of a regulatory element, such as the deletion of a tissue-specific negative  
regulatory element. Alternatively, the targeting event may replace an existing element; for  
example, a tissue-specific enhancer can be replaced by an enhancer that has broader or  
different cell-type specificity than the naturally occurring elements. Here, the naturally

occurring sequences are deleted and new sequences are added. In all cases, the  
5 identification of the targeting event may be facilitated by the use of one or more selectable  
marker genes that are contiguous with the targeting DNA, allowing for the selection of  
cells in which the exogenous DNA has integrated into the host cell genome. The  
identification of the targeting event may also be facilitated by the use of one or more  
marker genes exhibiting the property of negative selection, such that the negatively  
10 selectable marker is linked to the exogenous DNA, but configured such that the negatively  
selectable marker flanks the targeting sequence, and such that a correct homologous  
recombination event with sequences in the host cell genome does not result in the stable  
integration of the negatively selectable marker. Markers useful for this purpose include  
the Herpes Simplex Virus thymidine kinase (TK) gene or the bacterial xanthine-guanine  
15 phosphoribosyl-transferase (gpt) gene.

The gene targeting or gene activation techniques which can be used in accordance  
with this aspect of the invention are more particularly described in U.S. Patent No.  
5,272,071 to Chappel; U.S. Patent No. 5,578,461 to Sherwin et al.; International  
Application No. PCT/US92/09627 (WO93/09222) by Selden et al.; and International  
20 Application No. PCT/US90/06436 (WO91/06667) by Skoultchi et al., each of which is  
incorporated by reference herein in its entirety.

#### 5.4. POLYPEPTIDES OF THE INVENTION

25 The isolated polypeptides of the invention include, but are not limited to, a  
polypeptide comprising the amino acid sequence of SEQ ID NO:3. The polypeptides of  
the invention further include polypeptides which comprise one or more specific domains  
of the amino acid sequence in SEQ ID NO: 3.

The polypeptides of the present invention further include, but are not limited to, a  
30 polypeptide comprising the amino acid sequence encoded by the cDNA insert of clone  
p12616HY deposited with the American Type Culture Collection (ATCC; 10801  
University Blvd., Manassas, Virginia, 20110-2209, U.S.A.); a full length protein coding  
sequence of SEQ ID NO: 3 comprising the cDNA insert of clone p12616HY; a mature

protein coding sequence of SEQ ID NO: 3 comprising the cDNA insert of clone  
5 p12616HY.

Protein compositions of the present invention may further comprise an acceptable carrier, such as a hydrophilic, e.g., pharmaceutically acceptable, carrier.

The invention also relates to methods for producing a polypeptide comprising growing a culture of the cells of the invention in a suitable culture medium, and purifying  
10 the protein from the culture. For example, the methods of the invention include a process for producing a polypeptide in which a host cell containing a suitable expression vector that includes a polynucleotide of the invention is cultured under conditions that allow expression of the encoded polypeptide. The polypeptide can be recovered from the culture, conveniently from the culture medium, and further purified. Preferred  
15 embodiments include those in which the protein produced by such process is a full length or mature form of the protein.

The invention further provides a polypeptide including an amino acid sequence that is substantially equivalent to SEQ ID NOS: 3. Polypeptides according to the invention can have at least about 95%, and more typically at least about 98%, sequence identity to SEQ  
20 ID NO: 3.

The present invention further provides isolated polypeptides encoded by the nucleic acid fragments of the present invention or by degenerate variants of the nucleic acid fragments of the present invention. By "degenerate variant" is intended nucleotide  
25 fragments which differ from a nucleic acid fragment of the present invention (e.g., an ORF) by nucleotide sequence but, due to the degeneracy of the genetic code, encode an identical polypeptide sequence. Preferred nucleic acid fragments of the present invention are the ORFs that encode proteins. A variety of methodologies known in the art can be utilized to obtain any one of the isolated polypeptides or proteins of the present invention.  
30 At the simplest level, the amino acid sequence can be synthesized using commercially available peptide synthesizers. This is particularly useful in producing small peptides and fragments of larger polypeptides. Fragments are useful, for example, in generating antibodies against the native polypeptide. In an alternative method, the polypeptide or

protein is purified from bacterial cells which naturally produce the polypeptide or protein.

5 One skilled in the art can readily follow known methods for isolating polypeptides and proteins in order to obtain one of the isolated polypeptides or proteins of the present invention. These include, but are not limited to, immunochromatography, HPLC, size-exclusion chromatography, ion-exchange chromatography, and immuno-affinity chromatography. See, e.g., Scopes, *Protein Purification: Principles and Practice*,  
10 Springer-Verlag (1994); Sambrook, *et al.*, in *Molecular Cloning: A Laboratory Manual*; Ausubel *et al.*, *Current Protocols in Molecular Biology*.

The polypeptides and proteins of the present invention can alternatively be purified from cells which have been altered to express the desired polypeptide or protein. As used herein, a cell is said to be altered to express a desired polypeptide or protein when the cell,  
15 through genetic manipulation, is made to produce a polypeptide or protein which it normally does not produce or which the cell normally produces at a lower level. One skilled in the art can readily adapt procedures for introducing and expressing either recombinant or synthetic sequences into eukaryotic or prokaryotic cells in order to generate a cell which produces one of the polypeptides or proteins of the present invention.  
20 The purified polypeptides can be used in *in vitro* binding assays which are well known in the art to identify molecules which bind to the polypeptides. These molecules include but are not limited to, for e.g., small molecules, molecules from combinatorial libraries, antibodies or other proteins. The molecules identified in the binding assay are then tested  
25 for antagonist or agonist activity in *in vivo* tissue culture or animal models that are well known in the art. In brief, the molecules are titrated into a plurality of cell cultures or animals and then tested for either cell/animal death or prolonged survival of the animal/cells.

In addition, the binding molecules may be complexed with toxins, e.g., ricin or  
30 cholera, or with other compounds that are toxic to cells. The toxin-binding molecule complex is then targeted to a tumor or other cell by the specificity of the binding molecule for SEQ ID NOS: 3.

The protein of the invention may also be expressed as a product of transgenic



animals, e.g., as a component of the milk of transgenic cows, goats, pigs, or sheep which  
5 are characterized by somatic or germ cells containing a nucleotide sequence encoding the  
protein.

The protein may also be produced by known conventional chemical synthesis. Methods for constructing the proteins of the present invention by synthetic means are known to those skilled in the art. The synthetically-constructed protein sequences, by  
10 virtue of sharing primary, secondary or tertiary structural and/or conformational characteristics with proteins may possess biological properties in common therewith, including protein activity. Thus, they may be employed as biologically active or immunological substitutes for natural, purified proteins in screening of therapeutic compounds and in immunological processes for the development of antibodies.

15 The proteins provided herein also include proteins characterized by amino acid sequences similar to those of purified proteins but into which modification are naturally provided or deliberately engineered. For example, modifications in the peptide or DNA sequences can be made by those skilled in the art using known techniques. Modifications of interest in the protein sequences may include the alteration, substitution, replacement,  
20 insertion or deletion of a selected amino acid residue in the coding sequence. For example, one or more of the cysteine residues may be deleted or replaced with another amino acid to alter the conformation of the molecule. Techniques for such alteration, substitution, replacement, insertion or deletion are well known to those skilled in the art (see, e.g., U.S.  
25 Pat. No. 4,518,584). Preferably, such alteration, substitution, replacement, insertion or deletion retains the desired activity of the protein.

Other fragments and derivatives of the sequences of proteins which would be expected to retain protein activity in whole or in part and may thus be useful for screening or other immunological methodologies may also be easily made by those skilled in the art  
30 given the disclosures herein. Such modifications are believed to be encompassed by the present invention.

The protein may also be produced by operably linking the isolated polynucleotide of the invention to suitable control sequences in one or more insect expression vectors, and

employing an insect expression system. Materials and methods for baculovirus/insect cell expression systems are commercially available in kit form from, e.g., Invitrogen, San Diego, Calif., U.S.A. (the MaxBat.RTM. kit), and such methods are well known in the art, as described in Summers and Smith, Texas Agricultural Experiment Station Bulletin No. 1555 (1987), incorporated herein by reference. As used herein, an insect cell capable of expressing a polynucleotide of the present invention is "transformed."

10 The protein of the invention may be prepared by culturing transformed host cells under culture conditions suitable to express the recombinant protein. The resulting expressed protein may then be purified from such culture (i.e., from culture medium or cell extracts) using known purification processes, such as gel filtration and ion exchange chromatography. The purification of the protein may also include an affinity column  
15 containing agents which will bind to the protein; one or more column steps over such affinity resins as concanavalin A-agarose, heparin-toyopearl.RTM. or Cibacrom blue 3GA Sepharose.RTM.; one or more steps involving hydrophobic interaction chromatography using such resins as phenyl ether, butyl ether, or propyl ether; or immunoaffinity chromatography.

20 Alternatively, the protein of the invention may also be expressed in a form which will facilitate purification. For example, it may be expressed as a fusion protein, such as those of maltose binding protein (MBP), glutathione-S-transferase (GST) or thioredoxin (TRX). Kits for expression and purification of such fusion proteins are commercially  
25 available from New England BioLab (Beverly, Mass.), Pharmacia (Piscataway, N.J.) and In Vitrogen, respectively. The protein can also be tagged with an epitope and subsequently purified by using a specific antibody directed to such epitope. One such epitope ("Flag") is commercially available from Kodak (New Haven, Conn.).

Finally, one or more reverse-phase high performance liquid chromatography  
30 (RP-HPLC) steps employing hydrophobic RP-HPLC media, e.g., silica gel having pendant methyl or other aliphatic groups, can be employed to further purify the protein. Some or all of the foregoing purification steps, in various combinations, can also be employed to provide a substantially homogeneous isolated recombinant protein. The protein thus purified is

substantially free of other mammalian proteins and is defined in accordance with the present invention as an "isolated protein."

The polypeptide sequences encoded by SEQ ID No. 3 have numerous applications in techniques known to those skilled in the art of molecular biology. The polypeptides of the invention are related to the chemokine family of proteins as demonstrated by the highly-conserved cysteine residues of this family. The polypeptides of the invention and/or their agonists and antagonists are useful in methods for preventing neutropenia, preventing or augmenting inflammatory or other immune responses, and inhibiting diseased states associated with the hyperproliferative states of progenitor cells. The polypeptides of the invention may also be used to generate antibodies for diagnosis or therapy of activated or inflamed cells and/or tissues.

#### 5.4. DEPOSIT OF CLONES

The following clone, p12616HY was deposited with the American Type Culture Collection (ATCC) 10801 University Avenue, Manassas, Virginia, on December 22, 1998 under the terms of the Budapest Treaty. The 753 base pair cDNA insert of clone p12616HY is contained in vector pT7T3Pac. The 3' end of the cDNA is at the EcoR1 site of the vector. The clone represent a plasmid clone as described in the Examples set forth below.

25	Microorganism/Clone	ATCC Accession No.
	p12616HY	---

30

#### 5.5. USES AND BIOLOGICAL ACTIVITY

The polynucleotides and proteins of the present invention are expected to exhibit

one or more of the uses or biological activities (including those associated with assays  
5 cited herein) identified below. Uses or activities described for proteins of the present  
invention may be provided by administration or use of such proteins or by administration  
or use of polynucleotides encoding such proteins (such as, for example, in gene therapies  
or vectors suitable for introduction of DNA).

#### 10 5.5.1. RESEARCH USES AND UTILITIES

The polynucleotides provided by the present invention can be used by the research  
community for various purposes. The polynucleotides can be used to express recombinant  
protein for analysis, characterization or therapeutic use; as markers for tissues in which the  
corresponding protein is preferentially expressed (either constitutively or at a particular  
15 stage of tissue differentiation or development or in disease states); as molecular weight  
markers on Southern gels; as chromosome markers or tags (when labeled) to identify  
chromosomes or to map related gene positions; to compare with endogenous DNA  
sequences in patients to identify potential genetic disorders; as probes to hybridize and  
thus discover novel, related DNA sequences; as a source of information to derive PCR  
20 primers for genetic fingerprinting; as a probe to "subtract-out" known sequences in the  
process of discovering other novel polynucleotides; for selecting and making oligomers for  
attachment to a "gene chip" or other support, including for examination of expression  
patterns; to raise anti-protein antibodies using DNA immunization techniques; and as an  
25 antigen to raise anti-DNA antibodies or elicit another immune response. Where the  
polynucleotide encodes a protein which binds or potentially binds to another protein (such  
as, for example, in a receptor-ligand interaction), the polynucleotide can also be used in  
interaction trap assays (such as, for example, that described in Gyuris et al., Cell 75:791-  
803 (1993)) to identify polynucleotides encoding the other protein with which binding  
30 occurs or to identify inhibitors of the binding interaction.

The proteins provided by the present invention can similarly be used in assay to  
determine biological activity, including in a panel of multiple proteins for high-throughput  
screening; to raise antibodies or to elicit another immune response; as a reagent (including

the labeled reagent) in assays designed to quantitatively determine levels of the protein (or  
5 its receptor) in biological fluids; as markers for tissues in which the corresponding protein  
is preferentially expressed (either constitutively or at a particular stage of tissue  
differentiation or development or in a disease state); and, of course, to isolate correlative  
receptors or ligands. Where the protein binds or potentially binds to another protein (such  
as, for example, in a receptor-ligand interaction), the protein can be used to identify the  
10 other protein with which binding occurs or to identify inhibitors of the binding interaction.  
Proteins involved in these binding interactions can also be used to screen for peptide or  
small molecule inhibitors or agonists of the binding interaction.

Any or all of these research utilities are capable of being developed into reagent  
grade or kit format for commercialization as research products.

15 Methods for performing the uses listed above are well known to those skilled in the  
art. References disclosing such methods include without limitation "Molecular Cloning: A  
Laboratory Manual", 2d ed., Cold Spring Harbor Laboratory Press, Sambrook, J., E. F.  
Fritsch and T. Maniatis eds., 1989, and "Methods in Enzymology: Guide to Molecular  
Cloning Techniques", Academic Press, Berger, S. L. and A. R. Kimmel eds., 1987.  
20

#### 5.5.2. NUTRITIONAL USES

Polynucleotides and proteins of the present invention can also be used as  
nutritional sources or supplements. Such uses include without limitation use as a protein or  
25 amino acid supplement, use as a carbon source, use as a nitrogen source and use as a  
source of carbohydrate. In such cases the protein or polynucleotide of the invention can be  
added to the feed of a particular organism or can be administered as a separate solid or  
liquid preparation, such as in the form of powder, pills, solutions, suspensions or capsules.  
In the case of microorganisms, the protein or polynucleotide of the invention can be added  
30 to the medium in or on which the microorganism is cultured.

#### 5.5.3. CYTOKINE AND CELL PROLIFERATION/ DIFFERENTIATION ACTIVITY

A protein of the present invention may exhibit cytokine, cell proliferation (either

inducing or inhibiting) or cell differentiation (either inducing or inhibiting) activity or may induce production of other cytokines in certain cell populations. A polynucleotide of the invention can encode a polypeptide exhibiting such attributes. Many protein factors discovered to date, including all known cytokines, have exhibited activity in one or more factor-dependent cell proliferation assays, and hence the assays serve as a convenient confirmation of cytokine activity. The activity of a protein of the present invention is evidenced by any one of a number of routine factor dependent cell proliferation assays for cell lines including, without limitation, 32D, DA2, DA1G, T10, B9, B9/11, BaF3, MC9/G, M+(preB M+), 2E8, RB5, DA1, 123, T1165, HT2, CTLL2, TF-1, Mo7e and CMK. The activity of a protein of the invention may, among other means, be measured by the following methods:

Assays for T-cell or thymocyte proliferation include without limitation those described in: Current Protocols in Immunology, Ed by J. E. Coligan, A. M. Kruisbeek, D. H. Margulies, E. M. Shevach, W. Strober, Pub. Greene Publishing Associates and Wiley-Interscience (Chapter 3, In Vitro assays for Mouse Lymphocyte Function 3.1-3.19; Chapter 7, Immunologic studies in Humans); Takai et al., J. Immunol. 137:3494-3500, 1986; Bertagnolli et al., J. Immunol. 145:1706-1712, 1990; Bertagnolli et al., Cellular Immunology 133:327-341, 1991; Bertagnolli, et al., I. Immunol. 149:3778-3783, 1992; Bowman et al., I. Immunol. 152:1756-1761, 1994.

Assays for cytokine production and/or proliferation of spleen cells, lymph node cells or thymocytes include, without limitation, those described in: Polyclonal T cell stimulation, Kruisbeek, A. M. and Shevach, E. M. In Current Protocols in Immunology. J. E. e.a. Coligan eds. Vol 1 pp. 3.12.1-3.12.14, John Wiley and Sons, Toronto. 1994; and Measurement of mouse and human interleukin .gamma., Schreiber, R. D. In Current Protocols in Immunology. J. E. e.a. Coligan eds. Vol 1 pp. 6.8.1-6.8.8, John Wiley and Sons, Toronto. 1994.

Assays for proliferation and differentiation of hematopoietic and lymphopoietic cells include, without limitation, those described in: Measurement of Human and Murine Interleukin 2 and Interleukin 4, Bottomly, K., Davis, L. S. and Lipsky, P. E. In Current

- Protocols in Immunology. J. E. e.a. Coligan eds. Vol 1 pp. 6.3.1-6.3.12, John Wiley and Sons, Toronto. 1991; deVries et al., J. Exp. Med. 173:1205-1211, 1991; Moreau et al.,  
5 Nature 336:690-692, 1988; Greenberger et al., Proc. Natl. Acad. Sci. U.S.A. 80:2931-2938, 1983; Measurement of mouse and human interleukin 6--Nordan, R. In Current  
Protocols in Immunology. J. E. e.a. Coligan eds. Vol 1 pp. 6.6.1-6.6.5, John Wiley and Sons, Toronto. 1991; Smith et al., Proc. Natl. Acad. Sci. U.S.A. 83:1857-1861, 1986;  
10 Measurement of human Interleukin 11--Bennett, F., Giannotti, J., Clark, S. C. and Turner, K. J. In Current Protocols in Immunology. J. E. e.a. Coligan eds. Vol 1 pp. 6.15.1 John  
Wiley and Sons, Toronto. 1991; Measurement of mouse and human Interleukin 9--  
Ciarletta, A., Giannotti, J., Clark, S. C. and Turner, K. J. In Current Protocols in  
Immunology. J. E. e.a. Coligan eds. Vol 1 pp. 6.13.1, John Wiley and Sons, Toronto.  
15 1991.

- Assays for T-cell clone responses to antigens (which will identify, among others, proteins that affect APC-T cell interactions as well as direct T-cell effects by measuring proliferation and cytokine production) include, without limitation, those described in:  
Current Protocols in Immunology, Ed by J. E. Coligan, A. M. Kruisbeek, D. H. Margulies,  
20 E. M. Shevach, W Strober, Pub. Greene Publishing Associates and Wiley-Interscience  
(Chapter 3, In Vitro assays for Mouse Lymphocyte Function; Chapter 6, Cytokines and their cellular receptors; Chapter 7, Immunologic studies in Humans); Weinberger et al.,  
Proc. Natl. Acad. Sci. USA 77:6091-6095, 1980; Weinberger et al., Eur. J. Immun.  
11:405-411, 1981; Takai et al., J. Immunol. 137:3494-3500, 1986; Takai et al., J.  
25 Immunol. 140:508-512, 1988.

#### **5.5.4. IMMUNE STIMULATING OR SUPPRESSING ACTIVITY**

- A protein of the present invention may also exhibit immune stimulating or immune  
30 suppressing activity, including without limitation the activities for which assays are  
described herein. A polynucleotide of the invention can encode a polypeptide exhibiting  
such activities. A protein may be useful in the treatment of various immune deficiencies  
and disorders (including severe combined immunodeficiency (SCID)), e.g., in regulating

(up or down) growth and proliferation of T and/or B lymphocytes, as well as effecting the  
5 cytolytic activity of NK cells and other cell populations. These immune deficiencies may  
be genetic or be caused by viral (e.g., HIV) as well as bacterial or fungal infections, or may  
result from autoimmune disorders. More specifically, infectious diseases caused by viral,  
bacterial, fungal or other infection may be treatable using a protein of the present  
invention, including infections by HIV, hepatitis viruses, herpesviruses, mycobacteria,  
10 Leishmania spp., malaria spp. and various fungal infections such as candidiasis. Of course,  
in this regard, a protein of the present invention may also be useful where a boost to the  
immune system generally may be desirable, i.e., in the treatment of cancer.

Autoimmune disorders which may be treated using a protein of the present  
invention include, for example, connective tissue disease, multiple sclerosis, systemic  
15 lupus erythematosus, rheumatoid arthritis, autoimmune pulmonary inflammation,  
Guillain-Barre syndrome, autoimmune thyroiditis, insulin dependent diabetes mellitus,  
myasthenia gravis, graft-versus-host disease and autoimmune inflammatory eye disease.  
Such a protein of the present invention may also be useful in the treatment of allergic  
reactions and conditions, such as asthma (particularly allergic asthma) or other respiratory  
20 problems. Other conditions, in which immune suppression is desired (including, for  
example, organ transplantation), may also be treatable using a protein of the present  
invention.

Using the proteins of the invention it may also be possible to modulate immune responses, in  
25 a number of ways. Down regulation may be in the form of inhibiting or blocking an  
immune response already in progress or may involve preventing the induction of an  
immune response. The functions of activated T cells may be inhibited by suppressing T  
cell responses or by inducing specific tolerance in T cells, or both. Immunosuppression of  
T cell responses is generally an active, non-antigen-specific, process which requires  
30 continuous exposure of the T cells to the suppressive agent. Tolerance, which involves  
inducing non-responsiveness or anergy in T cells, is distinguishable from  
immunosuppression in that it is generally antigen-specific and persists after exposure to  
the tolerizing agent has ceased. Operationally, tolerance can be demonstrated by the lack



of a T cell response upon reexposure to specific antigen in the absence of the tolerizing agent.

5 Down regulating or preventing one or more antigen functions (including without limitation B lymphocyte antigen functions (such as, for example, B7)), e.g., preventing high level lymphokine synthesis by activated T cells, will be useful in situations of tissue, skin and organ transplantation and in graft-versus-host disease (GVHD). For example, 10 blockage of T cell function should result in reduced tissue destruction in tissue transplantation. Typically, in tissue transplants, rejection of the transplant is initiated through its recognition as foreign by T cells, followed by an immune reaction that destroys the transplant. The administration of a molecule which inhibits or blocks interaction of a B7 lymphocyte antigen with its natural ligand(s) on immune cells (such as a soluble, 15 monomeric form of a peptide having B7-2 activity alone or in conjunction with a monomeric form of a peptide having an activity of another B lymphocyte antigen (e.g., B7-1, B7-3) or blocking antibody), prior to transplantation can lead to the binding of the molecule to the natural ligand(s) on the immune cells without transmitting the corresponding costimulatory signal. Blocking B lymphocyte antigen function in this 20 matter prevents cytokine synthesis by immune cells, such as T cells, and thus acts as an immunosuppressant. Moreover, the lack of costimulation may also be sufficient to anergize the T cells, thereby inducing tolerance in a subject. Induction of long-term tolerance by B lymphocyte antigen-blocking reagents may avoid the necessity of repeated administration of these blocking reagents. To achieve sufficient immunosuppression or 25 tolerance in a subject, it may also be necessary to block the function of a combination of B lymphocyte antigens.

The efficacy of particular blocking reagents in preventing organ transplant rejection or GVHD can be assessed using animal models that are predictive of efficacy in 30 humans. Examples of appropriate systems which can be used include allogeneic cardiac grafts in rats and xenogeneic pancreatic islet cell grafts in mice, both of which have been used to examine the immunosuppressive effects of CTLA4Ig fusion proteins in vivo as described in Lenschow et al., Science 257:789-792 (1992) and Turka et al., Proc. Natl.

Acad. Sci USA, 89:11102-11105 (1992). In addition, murine models of GVHD (see Paul  
5 ed., Fundamental Immunology, Raven Press, New York, 1989, pp. 846-847) can be used  
to determine the effect of blocking B lymphocyte antigen function in vivo on the  
development of that disease.

Blocking antigen function may also be therapeutically useful for treating  
autoimmune diseases. Many autoimmune disorders are the result of inappropriate  
10 activation of T cells that are reactive against self tissue and which promote the production  
of cytokines and autoantibodies involved in the pathology of the diseases. Preventing the  
activation of autoreactive T cells may reduce or eliminate disease symptoms.  
Administration of reagents which block costimulation of T cells by disrupting  
receptor:ligand interactions of B lymphocyte antigens can be used to inhibit T cell  
15 activation and prevent production of autoantibodies or T cell-derived cytokines which may  
be involved in the disease process. Additionally, blocking reagents may induce antigen-  
specific tolerance of autoreactive T cells which could lead to long-term relief from the  
disease. The efficacy of blocking reagents in preventing or alleviating autoimmune  
disorders can be determined using a number of well-characterized animal models of  
20 human autoimmune diseases. Examples include murine experimental autoimmune  
encephalitis, systemic lupus erythematosus in MRL/lpr/lpr mice or NZB hybrid mice,  
murine autoimmune collagen arthritis, diabetes mellitus in NOD mice and BB rats, and  
murine experimental myasthenia gravis (see Paul ed., Fundamental Immunology, Raven  
25 Press, New York, 1989, pp. 840-856).

Upregulation of an antigen function (preferably a B lymphocyte antigen function),  
as a means of up regulating immune responses, may also be useful in therapy.  
Upregulation of immune responses may be in the form of enhancing an existing immune  
response or eliciting an initial immune response. For example, enhancing an immune  
30 response through stimulating B lymphocyte antigen function may be useful in cases of  
viral infection. In addition, systemic viral diseases such as influenza, the common cold,  
and encephalitis might be alleviated by the administration of stimulatory forms of B  
lymphocyte antigens systemically.

Alternatively, anti-vital immune responses may be enhanced in an infected patient  
5 by removing T cells from the patient, costimulating the T cells in vitro with viral antigen-  
pulsed APCs either expressing a peptide of the present invention or together with a  
stimulatory form of a soluble peptide of the present invention and reintroducing the in  
vitro activated T cells into the patient. Another method of enhancing anti-viral immune  
responses would be to isolate infected cells from a patient, transfect them with a nucleic  
10 acid encoding a protein of the present invention as described herein such that the cells  
express all or a portion of the protein on their surface, and reintroduce the transfected cells  
into the patient. The infected cells would now be capable of delivering a costimulatory  
signal to, and thereby activate, T cells in vivo.

The presence of the peptide of the present invention having the activity of a B  
15 lymphocyte antigen(s) on the surface of the tumor cell provides the necessary  
costimulation signal to T cells to induce a T cell mediated immune response against the  
transfected tumor cells. In addition, tumor cells which lack MHC class I or MHC class II  
molecules, or which fail to reexpress sufficient mounts of MHC class I or MHC class II  
molecules, can be transfected with nucleic acid encoding all or a portion of (e.g., a  
20 cytoplasmic-domain truncated portion) of an MHC class I  $\alpha$  .alpha. chain protein and  
.beta..sub.2 microglobulin protein or an MHC class II .alpha. chain protein and an MHC  
class II .beta. chain protein to thereby express MHC class I or MHC class II proteins on  
the cell surface. Expression of the appropriate class I or class II MHC in conjunction with  
25 a peptide having the activity of a B lymphocyte antigen (e.g., B7-1, B7-2, B7-3) induces a  
T cell mediated immune response against the transfected tumor cell. Optionally, a gene  
encoding an antisense construct which blocks expression of an MHC class II associated  
protein, such as the invariant chain, can also be cotransfected with a DNA encoding a  
peptide having the activity of a B lymphocyte antigen to promote presentation of tumor  
30 associated antigens and induce tumor specific immunity. Thus, the induction of a T cell  
mediated immune response in a human subject may be sufficient to overcome tumor-  
specific tolerance in the subject.

The activity of a protein of the invention may, among other means, be measured by

the following methods:

- 5        Suitable assays for thymocyte or splenocyte cytotoxicity include, without limitation, those described in: Current Protocols in Immunology, Ed by J. E. Coligan, A. M. Kruisbeek, D. H. Margulies, E. M. Shevach, W. Strober, Pub. Greene Publishing Associates and Wiley-Interscience (Chapter 3, In Vitro assays for Mouse Lymphocyte Function 3.1-3.19; Chapter 7, Immunologic studies in Humans); Herrmann et al., Proc. Natl. Acad. Sci. USA 78:2488-2492, 1981; Herrmann et al., J. Immunol. 128:1968-1974, 1982; Handa et al., J. Immunol. 135:1564-1572, 1985; Takai et al., I. Immunol. 137:3494-3500, 1986; Takai et al., J. Immunol. 140:508-512, 1988; Herrmann et al., Proc. Natl. Acad. Sci. USA 78:2488-2492, 1981; Herrmann et al., J. Immunol. 128:1968-1974, 1982; Handa et al., J. Immunol. 135:1564-1572, 1985; Takai et al., J. Immunol. 137:3494-3500, 1986; Bowman et al., J. Virology 61:1992-1998; Takai et al., J. Immunol. 140:508-512, 1988; Bertagnolli et al., Cellular Immunology 133:327-341, 1991; Brown et al., J. Immunol. 153:3079-3092, 1994.

- 20        Assays for T-cell-dependent immunoglobulin responses and isotype switching (which will identify, among others, proteins that modulate T-cell dependent antibody responses and that affect Th1/Th2 profiles) include, without limitation, those described in: Maliszewski, J. Immunol. 144:3028-3033, 1990; and Assays for B cell function: In vitro antibody production, Mond, J. J. and Brunswick, M. In Current Protocols in Immunology. J. E. e.a. Coligan eds. Vol 1 pp. 3.8.1-3.8.16, John Wiley and Sons, Toronto. 1994.

- 25        Mixed lymphocyte reaction (MLR) assays (which will identify, among others, proteins that generate predominantly Th1 and CTL responses) include, without limitation, those described in: Current Protocols in Immunology, Ed by J. E. Coligan, A. M. Kruisbeek, D. H. Margulies, E. M. Shevach, W. Strober, Pub. Greene Publishing Associates and Wiley-Interscience (Chapter 3, In Vitro assays for Mouse Lymphocyte Function 3.1-3.19; Chapter 7, Immunologic studies in Humans); Takai et al., J. Immunol. 137:3494-3500, 1986; Takai et al., J. Immunol. 140:508-512, 1988; Bertagnolli et al., J. Immunol. 149:3778-3783, 1992.

Dendritic cell-dependent assays (which will identify, among others, proteins

expressed by dendritic cells that activate naive T-cells) include, without limitation, those described in: Guery et al., J. Immunol. 134:536-544, 1995; Inaba et al., Journal of Experimental Medicine 173:549-559, 1991; Macatonia et al., Journal of Immunology 154:5071-5079, 1995; Porgador et al., Journal of Experimental Medicine 182:255-260, 1995; Nair et al., Journal of Virology 67:4062-4069, 1993; Huang et al., Science 264:961-965, 1994; Macatonia et al., Journal of Experimental Medicine 169:1255-1264, 1989; Bhardwaj et al., Journal of Clinical Investigation 94:797-807, 1994; and Inaba et al., Journal of Experimental Medicine 172:631-640, 1990.

Assays for lymphocyte survival/apoptosis (which will identify, among others, proteins that prevent apoptosis after superantigen induction and proteins that regulate lymphocyte homeostasis) include, without limitation, those described in: Darzynkiewicz et al., Cytometry 13:795-808, 1992; Gorczyca et al., Leukemia 7:659-670, 1993; Gorczyca et al., Cancer Research 53:1945-1951, 1993; Itoh et al., Cell 66:233-243, 1991; Zacharchuk, Journal of Immunology 145:4037-4045, 1990; Zamai et al., Cytometry 14:891-897, 1993; Gorczyca et al., International Journal of Oncology 1:639-648, 1992.

Assays for proteins that influence early steps of T-cell commitment and development include, without limitation, those described in: Antica et al., Blood 84:111-117, 1994; Fine et al., Cellular Immunology 155:111-122, 1994; Galy et al., Blood 85:2770-2778, 1995; Toki et al., Proc. Nat. Acad. Sci. USA 88:7548-7551, 1991.

#### **5.5.5. HEMATOPOIESIS REGULATING ACTIVITY**

A protein of the present invention may be useful in regulation of hematopoiesis and, consequently, in the treatment of myeloid or lymphoid cell deficiencies. Even marginal biological activity in support of colony forming cells or of factor-dependent cell lines indicates involvement in regulating hematopoiesis, e.g. in supporting the growth and proliferation of erythroid progenitor cells alone or in combination with other cytokines, thereby indicating utility, for example, in treating various anemias or for use in conjunction with irradiation/chemotherapy to stimulate the production of erythroid precursors and/or erythroid cells; in supporting the growth and proliferation of myeloid